Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX:PBT) covers the month of May 2012. The document serves as a Change of Director's Interest Notice filed with the Australian Securities Exchange (ASX) and furnished to the SEC. The registrant is a foreign private issuer based in Victoria, Australia.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding a specific director's shareholding change and does not contain financial statements or operational metrics.
Material Changes
The primary material change disclosed is an increase in the shareholding of Director Geoffrey Kempler on May 1, 2012:
- Transaction Type: On-market acquisition.
- Shares Acquired: 156,000 Fully Paid Ordinary shares.
- Consideration: $25,131.
- Holdings Prior to Change: 17,655,000 total shares (30,000 direct; 17,625,000 indirect).
- Holdings After Change: 17,811,000 total shares (30,000 direct; 17,781,000 indirect).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the disclosure of the director's interest change.
Investor Verification Checklist
- Verify the current market price of Prana Biotechnology Limited (ASX:PBT) shares to contextualize the $25,131 acquisition value.
- Confirm the total number of issued shares outstanding to calculate the director's percentage ownership post-transaction.
- Review recent ASX announcements for any other director trading activity or material corporate developments during May 2012.
- Check the company's latest Form 20-F or annual report for comprehensive financial performance data not included in this 6-K.